Skip to content

Firm Record

Suretec Innovations, LLC

7 findings from 2 inspection documents published by regulators. Each row below says what its date means.

US FDA · 2026-08-18 ~ 2026-10-23

Areas cited

Complaint and recall handlingLaboratory and QC controlsDeviation, CAPA, and investigationQuality unit oversight

Published inspection documents

Your firm failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(b)). You failed to ensure adequate microbiological testing for each batch of your drug product prior to release. Your non-compendial test method used to determine microbiological attributes (e.g., total count, objectionable microorganisms) for your finished OTC drug product was inadequate. Specifically, you lacked appropriate incubation times, lacked appropriate method suitability, and lacked positive and negative controls. In addition, you did not validate this non-compendial method. Your response is inadequate. You state that a contract laboratory will perform validation of United States Pharmacopeia (USP) <61> and <62> test methods for future release testing. While you submitted your Laboratory Controls and Test Method Management procedure and CAPA-2026-005, which references validation planning for microbiological methods, your response does not demonstrate adequate corrective actions to ensure that distributed product was appropriately tested prior to release, nor does it include a retrospective assessment of product quality. Testing is essential to ensure that the drug product you manufacture conform to all predetermined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished-product specifications and are suitable for release to consumers. In response to this letter, provide: A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision. An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter. A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard-quality drug products, take rapid corrective actions, such as notifying customers and product recalls. 2026-08-18 US FDA 3 findingsComplaint and recall handling · Deviation, CAPA, and investigation View the regulator's official source

21 CFR sections cited in FDA inspections

Citations from 1 FDA inspection (2026-03-05) of facilities listed under this company name in FDA's inspection citation data.

As written by FDAInspectionLatest inspection
21 CFR 211.160(b)Scientifically sound laboratory controls12026-03-05
21 CFR 211.165(a)Testing and release for distribution12026-03-05
21 CFR 211.22(a)Lack of quality control unit12026-03-05
21 CFR 211.22(d)Procedures not in writing, fully followed12026-03-05

1 site: SURETEC INNOVATIONS LLC (Gilbert, AZ, United States) · 1 inspection

Source: FDA Data Dashboard - Inspections Citations, as of 2026-11-08. Only inspections with at least one citation are included, and a section cited more than once in one inspection counts once. Only facilities whose name and legal form match this page's documents, and that are listed in a single country, are included.

Other companies with similar findings

Other companies with findings worded closely to this company's. Only documents of the same type are compared.

A record as of publication. Check the agency's own announcements for any later corrective action.

What is included. As collected on 2026-11-15: only documents with a detail page (3 or more findings). See the firm lookup for everything.

Full history of Suretec Innovations, LLC — including inspection classifications Browse by document Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.